Literature DB >> 10837378

Efficacy of occlusion for strabismic amblyopia: can an optimal duration be identified?

M Cleary1.   

Abstract

BACKGROUND/AIMS: The study of occlusion efficacy in amblyopia has been hampered by the use of non-logMAR acuity tests and a failure to assess threshold acuity for both eyes. These issues are addressed in the current study which compares the effect of spectacles alone and spectacles in combination with occlusion, with the use of the logMAR crowded test.
METHODS: Changes in uniocular and interocular acuity differences were compared for two age matched groups of previously untreated children with strabismic amblyopia: one compliant with spectacles only (n = 17, mean 6.2 (SD 2.5) years) and the other with spectacles and occlusion (n = 69, mean 5.1 (1) years) over a 1 year period. Changes in logMAR acuity were also analysed for a larger occluded group (n = 119) in response to successive 200 hour blocks of occlusion up to > or =1000 hours, in an attempt to isolate an optimal occlusion regime.
RESULTS: Visual acuity improved for more of the amblyopic eyes of the occluded (74%) than the spectacles only group (59%), and only one child from the latter group deteriorated. Mean visual acuity improved for both eyes of both treatment groups, but the change was significantly larger for the strabismic eyes of the occluded group overall and within the first 6 month period (p <0. 05). Occlusion was only effective for the first 400 hours worn. Subsequent visual improvement was bilateral and symmetrical.
CONCLUSION: Occlusion is more effective in the treatment of strabismic amblyopia than spectacles alone, and the effect is optimal within the first 6 months of wear. In terms of occlusion duration, maximal improvement occurs in response to 400 hours of occlusion wear or less, and to full time occlusion. Visual maturation continues, but is retarded for amblyopic eyes.

Entities:  

Mesh:

Year:  2000        PMID: 10837378      PMCID: PMC1723515          DOI: 10.1136/bjo.84.6.572

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  28 in total

1.  Stability of visual acuity in amblyopic patients after visual maturity.

Authors:  W E Scott; C F Dickey
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

Review 2.  Current trends in amblyopia therapy.

Authors:  J T Flynn; J C Cassady
Journal:  Ophthalmology       Date:  1978-05       Impact factor: 12.079

3.  Identifying amblyopia using associated conditions, acuity, and nonacuity features.

Authors:  M C Flom; H E Bedell
Journal:  Am J Optom Physiol Opt       Date:  1985-03

4.  Natural history of amblyopia untreated owing to lack of compliance.

Authors:  K Simons; M Preslan
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

5.  Contrast sensitivity and acuity relationship in strabismic and anisometropic amblyopia.

Authors:  M Abrahamsson; J Sjöstrand
Journal:  Br J Ophthalmol       Date:  1988-01       Impact factor: 4.638

6.  The sensitive period: transfer of fixation after occlusion for strabismic amblyopia.

Authors:  A A Assaf
Journal:  Br J Ophthalmol       Date:  1982-01       Impact factor: 4.638

7.  Increased drift in amblyopic eyes.

Authors:  K J Ciuffreda; R V Kenyon; L Stark
Journal:  Br J Ophthalmol       Date:  1980-01       Impact factor: 4.638

8.  The threshold contrast sensitivity function in strabismic amblyopia: evidence for a two type classification.

Authors:  R F Hess; E R Howell
Journal:  Vision Res       Date:  1977       Impact factor: 1.886

9.  Critical period for deprivation amblyopia in children.

Authors:  D Taylor
Journal:  Trans Ophthalmol Soc U K       Date:  1979

10.  Compliance and results of treatment for amblyopia in children more than 8 years old.

Authors:  M Oliver; R Neumann; Y Chaimovitch; N Gotesman; M Shimshoni
Journal:  Am J Ophthalmol       Date:  1986-09-15       Impact factor: 5.258

View more
  20 in total

1.  Differences in the management of amblyopia between European countries.

Authors:  J H Y Tan; J R Thompson; I Gottlob
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

2.  Amblyopia therapy.

Authors:  B W Fleck
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

3.  Treatment of unilateral visual impairment on preschool vision screening: study leaves questions unanswered.

Authors:  Hirekatur V Srinivas
Journal:  BMJ       Date:  2004-02-07

Review 4.  Improving the performance of the amblyopic visual system.

Authors:  Dennis M Levi; Roger W Li
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-02-12       Impact factor: 6.237

5.  A morphological study of amblyopic eyes in children failing to achieve normal visual acuity after electronically monitored long-term occlusion treatment.

Authors:  Claudia Kuhli-Hattenbach; Michael Janusz Koss; Thomas Kohnen; Maria Fronius
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-23       Impact factor: 3.117

6.  Amblyopia therapy in Asian children: factors affecting visual outcome and parents' perception of children's attitudes towards amblyopia treatment.

Authors:  Swati Handa; Audrey Chia
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

7.  Why is compliance with occlusion therapy for amblyopia so hard? A qualitative study.

Authors:  M Dixon-Woods; M Awan; I Gottlob
Journal:  Arch Dis Child       Date:  2006-03-10       Impact factor: 3.791

8.  Current concepts in the management of amblyopia.

Authors:  Blanca Ruiz de Zárate; Jaime Tejedor
Journal:  Clin Ophthalmol       Date:  2007-12

9.  Design of the Monitored Occlusion Treatment of Amblyopia Study (MOTAS).

Authors:  C E Stewart; A R Fielder; D A Stephens; M J Moseley
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

10.  Prolonged perceptual learning of positional acuity in adult amblyopia: perceptual template retuning dynamics.

Authors:  Roger W Li; Stanley A Klein; Dennis M Levi
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.